Michael Mark

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2021 · 336 citations

Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

Sabine Schmid, Oliver Gautschi, Sacha I. Rothschild et al. · Journal of Thoracic Oncology · 2016 · 72 citations · Full text

De Novo Egfr, Medicine, Pathology +6

The Influence of Two Different Hydroxyethyl Starch Solutions (6% HES 130/0.4 and 200/0.5) on Blood Viscosity

Thomas A. Neff, Lukas Fischler, Michael Mark et al. · Anesthesia & Analgesia · 2005 · 50 citations

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Solange Peters, Sarah Danson, Baktiar Hasan et al. · Journal of Thoracic Oncology · 2020 · 49 citations · Full text

Advanced Nsclc, Oncology, Splendour Trial +9

Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors

Arnoud J. Templeton, Beat Thürlimann, Michael R. Baumann et al. · BMC Cancer · 2013 · 43 citations · Full text